Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
46,025
Total Claims
$8.2M
Drug Cost
1,976
Beneficiaries
$4,171
Cost/Patient
Risk Score Breakdown 9/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+196%
Cost per patient vs peers
$4,171 vs $1,411 avg
+72%
Brand preference vs peers
18.3% vs 10.6% avg
Brand vs Generic
Brand: 8,272 claims · $6.4M
Generic: 36,878 claims · $1.8M
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dapagliflozin Propanediol | 1,078 | $1.4M |
| Sitagliptin Phos/Metformin Hcl | 587 | $727K |
| Sitagliptin Phosphate | 436 | $508K |
| Icosapent Ethyl | 572 | $414K |
| Empagliflozin | 322 | $386K |
| Budesonide/Formoterol Fumarate | 689 | $328K |
| Semaglutide | 252 | $291K |
| Tirzepatide | 192 | $242K |
| Rosuvastatin Calcium | 2,517 | $212K |
| Linaclotide | 216 | $191K |
| Apixaban | 163 | $175K |
| Dulaglutide | 125 | $163K |
| Fluticasone/Umeclidin/Vilanter | 190 | $157K |
| Metformin Hcl | 84 | $153K |
| Icosapent Ethyl | 270 | $149K |
Prescribing Profile
Patient Profile
73
Avg Age
62%
Female
1.38
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data